WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.074
Volume 7, Issue 15, 1028-1037. Review Article ISSN 2277– 7105

BIPOLAR DISORDER IMPACT ON AGE ONSET WITH GENETIC IMBALANCE

Praveen N. M.[1]*, Kiran B Muchadi[2], Manasa S.[3] and Dr. B. Y. Sathish Kumar[4]

Post Graduate Department of Biotechnology, JSS College, Ooty Road, Mysuru - 570025, Karnataka, India.

Article Received on
17 June 2018,

Revised on 08 July 2018,
Accepted on 29 July 2018,

DOI: 10.20959/wjpr201815-12958

***Corresponding Author**
Praveen N. M.
Postgraduate Department of Biotechnology, JSS College, Ooty Road, Mysuru - 570025, Karnataka, India.

ABSTRACT

Bipolar disorder persistent undiagnosed complex with diverse appearance which provides psychological healing with pharmacotherapy diminishes frequency, severity, manic and depressive episodes. Bipolar disorder targets on comorbid conditions such as panic, anxiety, and abuse, personality disorder evaluated in psychosocial risks for unipolar depression. We conclude that combination of variant therapies, age onset, genetic factors are influenced by cognitive behavioral therapies may help to cure bipolar disorder.

KEYWORDS: Bipolar Disorder, Mania, Depression, Genetic Factors.

INTRODUCTION

Bipolar disorder (BD) recommends various sporadic ailments that onset premorbid level of schizophrenia during heritable psychiatric condition with long-term grief and diminishes in childhood and adolescence. The impasse of BD I bash in manic episodes which characterized intense positive emotions with mess faced.[1,2] It serves as chronic conditions that present comorbidity with psychiatric conditions and high mortality[3], the life threating conditions were distinguish by mood episodes and depressive episodes arise in sleep disturbance of individuals endure insomnia or hypersomnia.[4] BD mainly focused on mania or bipolar depression which can be examined in neuroimaging studies.

Depression and schizophrenia overlapping phenomenology during increased metabolic activity of subcortical paralimbic that supports limbic cortical dysregulation in dorsal hypo-function of neocortical that produce virtual paralimbic activity.[5] Majority of inhabitants

comprised of a hyperthymic mood that encounters during unpredictable clinical practices it can be eradicated by appropriate supervision to patients.[6]

It considered as a multifarious inherent ailment that features disturbance in a mood which includes psychotic signs such as delusions and hallucinations whichepisodes mania in a lifetime. Unipolar depression experience pathological raise mood with distinctive nosological entities.[7] It commonly viewed in the manic phase that constitutes substantial public health problems in multiplex families across several generations.

EPIDEMIOLOGY

BD characterized as inherited from parents to offspring which influence in annoyance, dysphoric, compulsive, hyperactivity, mood obligation, and impulsivity. The frequency of BD has executed lifetime that includes multiple clinical aspects of mixed episodes, depression, and ailment occur equally in both the genders.[8] The clinical aspects arise with increased diabetes mellitus (DM), obesity and cardiovascular disease are most common in BD patients that cohorts age-matched and impact on a cardiovascular disease that susceptibility to metabolic syndrome with a psychiatric diagnosis.[9] BD firmly conventional flanked by violence and schizophrenia that indicates elevated morbid substance as an indicator of mental disorder with high risks that associate violence, child abuse, neglect, antisocial behavior and stressful life events.

AGE ONSET

The appearance of bipolar interferes with an adolescent that contribute depression, anxiety in adverse quality of life. It proved skin texture of psychiatric disorders for instant depression, obsessive-compulsive, hyperactivity disorder that shown in vast adolescent.[10] Episodes of restricted age predominance between 15-25 years age group with a longitudinal evolution of depressive mania with reverse direction. The onset of psychiatric disorder reveals nosological importance that features prognostics individuals in adulthood with longer manic episodes.[11]

It comprises hypomania in major and minor rigorousness that comparison of BD I & II with retrospective manic episodes occur in the lifetime of sub-threshold hypomania.[12] Children and adolescent with BD impaired both attention-deficit/hyperactivity disorder (ADHD) exhibit globally that impair unipolar, sub-syndromal BD, healthy teens and colleagues reports in dysfunction among school-age children which impairs multiple functional domains comorbidity in pediatric associate with psychosocial conditions.[13]

GENETICS

BD recognized genetic etiology of neuropsychiatric disease that involves multiple genesinvolves in genetic inheritance that detects effective gene for their spurious findings in linkage to chromosome 4p16, 12q23-q24, 18pcen-qcen, 18q22-q23 and 21q22.3.[14] It characterized severe mood, mania, and depression that accounts in massive families with contributing gene and environmental factors.[15]

These bipolar genomes are severe effects through psychiatric conditions associated with a CACNA1C gene mutation that encodes for alpha-1 subunit through calcium ions in neuro-regulators through muscle contraction in the heart.[16] BD exists for schizophrenia of anxiety disorders during dopamine breakdown of Catechol-O-Methyltransferaseon chromosome 22q11 implicated in prefrontal cortical function evidence in hyperactivity, obsessive neurotic ailment, phobic anxiety and anorexia nervosa.[17] The BD occursmode of inheritance with a complexity of multiple genetic factors which susceptibility loci in familial accretion linkage individual include chromosome 1, 4, 6,10,12,13,18,21,22, and X. Individual genes differ in a phenotypic model with genetic heterogeneity.[18]

ACUTE MANIA

Mania can be recognized as a bipolar disorder of infirmity, disgrace and perceptive diminishing which increases in antipsychotics in bipolar depression and manic treatment evidence during aggression, agitation, psychosis, poor judgment and social dysfunction.[19] The occurrence of hypomania is petite and pigeonholed by elevated vision, efficiency and cordiality while severe mania escorted by phobia, suicidality and diminished judgment, with disrupt sleep involves in a sensitive neurological imbalance that approaches impulsive system.[8,20]

ACUTE DEPRESSION

Over millions of people were facing acute depression that effects through any age group form childhood due to psychopathological conditions engage with low pressed mood, anhedonia or fatigue. Depression considered as comprehensive anxiety mess that consist risk factors in phobia like a metabolic disorder, arise in obesity that results in depression development. Acute depression has shown adverse to coronary artery diseases that probably interpret in adverse cardiac depression.[21,22]

It differentiate low mood with multiple cognitive and vegetative sign with various episodes of depressive disorder which shown clinical aspects like diabetes, heart disease, an autoimmune disorder, and ache are more common, meanwhile, they generally focused on monoamine neurotransmitters serotonin and norepinephrine.[23]

TREATMENT

The universal medications are used for bipolar depression are carbamazepine, quetiapine, ziprasidone**,** chlorpromazine, haloperidol, melatoninetc.,that influence prior medication history that characterized manic episodes, and presence of rapid cycling offers intramuscular injection and administration of oral therapy that adversely impacts on patients by variant pharmacological drugs. This medication may lead to life-threatening and fatal overdose.

CARBAMAZEPINE

The drug that sustains in healing of bipolar illness with the effectiveness of carbamazepine as prophylaxis against mania, bipolar depression, and BD as monotherapy treatment, that successfully impact on clinical conditions.[24,25]

QUETIAPINE

It supports effectiveness that confirmed post-hoc analyses with blind trail treatment that can reduce aggression in schizophrenia, with anti-aggressive effects as atypical antipsychotic.

Quetiapine used in effective treatment for BD in both genders, the combination of quetiapine along with divalproex used to prevent mood events in bipolar I disorder patients with highly depressive in nature.[26,27]

ZIPRASIDONE

It used randomly with haloperidol schizophrenia and schizoaffective disorder that supports effectively through antipsychotics.[27]

CHLORPROMAZINE

Chlorpromazines consider as first-generation antipsychotic with relatively and cram with lithium, haloperidol, and pimozide. Chlorpromazine affects multiple clinical conditions like extrapyramidal symptoms, tardive dyskinesia, and hepatoxicity.[28]

HALOPERIDOL

Haloperidol work as faster as onset on anti-manic action that carries multiple extra-pyramidal symptoms, tardive dyskinesia, and many others with evaluation of monotherapy healing with risperidone, olanzapine, quetiapine, ziprasidone.[28]

NON-PHARMACOLOGIC APPROACHES

Non-pharmacologic approach considers as traditional methods that helps to cure major depressive disorder especially in childhood adversity or recent stress. This non-pharmacological approach acts as neurostimulation techniques that insight on major depressive disorder by stimulation of vagus nerve, transcranial magnetic stimulation of prefrontal cortex and sub-genual cingulated.[23]

MELATONIN-RELATED APPROACHES

Melatonin acts as neurohormone that can secrete by a pineal gland in a circadian fashion; it inhibits light secretion through the suprachiasmatic nucleus. Melatonin comprises of agomelatine and ramelteon that fight against BD.[29]

ANTIDEPRESSANTS

Antidepressant considered as mono-therapy for bipolar II depression induced hypomania or mania involve pathophysiology depressive disorder that effects through neurotrophic factors with a growth regulating system that prevents structural brain abnormalities.[6,23]

MONOAMINE

Monoamine acts as an antidepressant that balance neurotransmission on mood regulation drugs includes MAOIs, TCAs, SSRIs, SNRIs, and the a2- adrenergic antagonist, mirtazapine which place a vital role in brain functioning and target on neurotransmission development.[30]

VALPROATE

Valproate acts as an effective treatment with mixed and classic mania on the rapid onset that produces clinical improvement with high frequency in BD teratogenicity on acute side effects recognized weight gain and hair loss.[28]

FAMILY-FOCUSED THERAPY

Involvement of family-focused therapy begins with psycho-educational involved in recurrence and developing relapse in multiple family members once, in the life course, treatment and self-management of BD need for the role of stress in provoking episodes with

the intervention of depression that enhance due to the reduction of adaptive communication skills.[31,32]

DEPRESSION-SPECIFIC PSYCHOTHERAPIES

Pharmacotherapy is an effective treatment for unipolar depression in combining interactive psychotherapy and pharmacotherapy that support the efficiency of acute cognitive therapy and achieve reduce risk recurrence as cognitive behavioral therapy that participant major depression.[21]

LITHIUM

Lithium appears to be effective classic mania that includes a narrow therapeutic index, poor tolerability, high dosages and risk of rebound mania that exists in a substantial reduction of renal function that remains unclear. The effective factors of lithium shown on hyperparathyroidism that increased during calcium concentration are most common side effects of lithium are the polydipsia, polyuria, and hypothyroidism.[28,33]

Depression cannot be distinguished from surrogate generation from nonlinear behavior that inference with nonlinearity mood in bipolar disorder that accounts uncomplicated co-morbidity with personality disorder that relates to various mental disorder impacts on euthymic patients that increases in abuse, suicidality and aggression exhibit in increased impulsivity.[29] Increased BD elevated on hypomanic demographic factors includes variety of socioeconomic status that strongly tied with emotion regulation disorder effects through multiple types of people in onset individual health and maintenance BD by using prospective illness by measuring self reported risk.[34] Recognition of clinical difficulties by diagnosing pharmacological treatment, abuse substance, anxiety conditions, personality disorder, martial relationship, child management, suicide risk, anger management and resistance treatment.[35]

The concurrent analysis of BD arise in onset patients might be distinct in reliability mainly episodes at probably age group which impact on mood disorder assassin comorbid illness, specifies moderate cohort prospectively.[36]

Bipolar illness approach traditionally between antipsychotics and anti-depressants which stabilize mood experiences anti-manic agents that provides effective and prevention of manic episodes by combination of fluoxetine and quetiapine.[18] It behaves as psychological and behavioral aspects with clinical conditions contributing to caregiver burden and premature

institutionalization that pre-exist bipolar diathesis or bipolar treatment alters pathoplastical alternation in clinical expression of dementia includes excitatory symptoms and mood liability with hypomania, and increase suicide.[37] Mood stabilizer precise stabilizer of anticonvulsant proves prophylactic for manic depressive illness in instance to sodium valproate due to lack of sedative drugs[38], psychosocial risk factors contribute onset, course or BD expression which supportive social and non-supportive interaction may occurs due to environmental features, includes cognitive behavioral therapy.[39]

BD verifies that effective concern and analysis with proper findings may generalized with psychiatric disorders may suggest appropriate treatment for a chronic disorder and chronic self management that found to be creativity of concerned patients may generate self management solution to discernment in BD population.

CONCLUSION

Bipolar disorder is more effective manic and depressive disorder episodes the efficiency of potential psychosocial risk factors by gene impact, environmental, mainly found in variant age onset. It conclude that cognitive impairments operates with multiple clinical regimens that helps to control severity of disorder by behavioral therapy, psycho-education and psychosocial approaches point for key success in improving functional outcome.

REFERENCE

1. Krieger fv, stringaris a. Bipolar disorder and disruptive mood dysregulation in children and adolescents: assessment, diagnosis and treatment. Evid Based Ment Health, 2013; 16(4): 93-4.
2. Edge, M. D., Miller, C. J., Muhtadie, L., Johnson, S. L., Carver, C. S., Marquinez, N., & Gotlib, I. H. People with bipolar I disorder report avoiding rewarding activities and dampening positive emotion. *Journal of Affective Disorders*, 2013; *146*(3): 407-413.
3. Álvarez, L. M., & Tamayo, J. M. Psychosocial interventions in bipolar disorder: a review. *Actas Esp Psiquiatr*, 2012; *40*(2): 84-92.
4. Latalova, K., Prasko, J., Kamaradova, D., Sedlackova, Z., & Ociskova, M. Co-morbidity bipolar disorder and personality disorders. *Neuro endocrinology Letters*, 2013; *34*(1): 1-8.
5. Malhi, G. S., Lagopoulos, J., Owen, A. M., & Yatham, L. N. Bipolaroids: functional imaging in bipolar disorder. *Acta Psychiatrica Scandinavica*, 2004; *110*(s422): 46-54.
6. Piver, A., Yatham, L. N., & Lam, R. W. Bipolar spectrum disorders. New perspectives. *Canadian family physician*, 2002; *48*(5): 896-904.

7. Craddock, N., & Jones, I. Genetics of bipolar disorder. *Journal of medical genetics*, 1999; *36*(8): 585-594.
8. Sit, D. (2004). Women and bipolar disorder across the life span. *Journal of the American Medical Women's Association 1972; 59*(2): 91.
9. Price, A. L., & Marzani-Nissen, G. R. Bipolar disorders: a review. *Am Fam Physician*, 2012; *85*(5): 483-493.
10. Phillips, K. A., Didie, E. R., Menard, W., Pagano, M. E., Fay, C., & Weisberg, R. B. Clinical features of body dysmorphic disorder in adolescents and adults. *Psychiatry research*, 2006; *141*(3): 305-314.
11. Beesdo, K., Höfler, M., Leibenluft, E., Lieb, R., Bauer, M., & Pfennig, A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. *Bipolar disorders*, 2009; *11*(6): 637-649.
12. Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M., Petukhova, M., & Kessler, R. C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Co-morbidity Survey replication. *Archives of general psychiatry*, 2007; *64*(5): 543-552.
13. Goldstein, T. R., Birmaher, B., Axelson, D., Goldstein, B. I., Gill, M. K., Esposito-Smythers, C., & Keller, M. Psychosocial functioning among bipolar youth. *Journal of affective disorders*, 2009; *114*(1): 174-183.
14. Detera-Wadleigh, S. D., Badner, J. A., Berrettini, W. H., Yoshikawa, T., Goldin, L. R., Turner, G.,& Esterling, L. E. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11. 2. *Proceedings of the National Academy of Sciences*, 1999; *96*(10): 5604-5609.
15. Barnett, J. H., & Smoller, J. W. The genetics of bipolar disorder. *Neuroscience*, 2009; *164*(1): 331-343.
16. Kerner, B. Genetics of bipolar disorder. *The application of clinical genetics*, 2014; *7:* 33.
17. Funke, B., Malhotra, A. K., Finn, C. T., Plocik, A. M., Lake, S. L., Lencz, T., & Kucherlapati, R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. *Behavioral and Brain Functions*, 2005; *1*(1): 19.
18. Fountoulakis, K. N., Vieta, E., Sanchez-Moreno, J., Kaprinis, S. G., Goikolea, J. M., & Kaprinis, G. S. Treatment guidelines for bipolar disorder: a critical review. *Journal of affective disorders*, 2005; *86*(1): 1-10.
19. Vieta, E., & Sanchez-Moreno, J. Acute and long-term treatment of mania. *Dialogues in clinical neuroscience*, 2005; *10*(2): 165.

20. Johnson, S. L., Cueller, A. K., Ruggero, C., Winett-Perlman, C., Goodnick, P., White, R., & Miller, I. Life events as predictors of mania and depression in bipolar I disorder. *Journal of abnormal psychology*, 2008; *117*(2): 268.
21. Kupfer, D. J., Frank, E., & Phillips, M. L. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. *The Lancet*, 2012; *379*(9820): 1045-1055.
22. Bondy, B. Pathophysiology of depression and mechanisms of treatment. *Dialogues in clinical neuroscience*, 2002; *4*: 7-20.
23. aan Het Rot, M., Mathew, S. J., & Charney, D. S. Neurobiological mechanisms in major depressive disorder. *Canadian Medical Association Journal*, 2009; *180*(3): 305-313.
24. Belmaker, R. H. Bipolar disorder. *New England Journal of Medicine*, 2004; *351*(5): 476-486.
25. Pratoomsri, W., Yatham, L. N., Bond, D. J., Lam, R. W., & Sohn, C. H. Oxcarbazepine in the treatment of bipolar disorder: a review. *The Canadian Journal of Psychiatry*, 2006; *51*(8): 540-545.
26. Muneer, A. Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. *Clinical Psycho pharmacology and Neuroscience*, 2015; *13*(1): 25.
27. Volavka, J. Violence in schizophrenia and bipolar disorder. *PsychiatriaDanubina*, 2013; *25*(1): 0-33.
28. Miklowitz, D. J., & Johnson, B. S. L. Social and familial factors in the course of bipolar disorder: basic processes and relevant interventions. *Clinical Psychology: Science and Practice*, *16*(2): 281-296.
29. Latalova, K., Prasko, J., Kamaradova, D., Grambal, A., Havlikova, P., Jelenova, D., & Sandoval, A. Bipolar disorder and sleep problems. *Act Nerv Super Rediviva*, 2013; *55*(4): 173-183.
30. Li, X., Frye, M. A., & Shelton, R. C Review of pharmacological treatment in mood disorders and future directions for drug development. *Neuro psycho pharmacology*, 2012; *37*(1): 77-101.
31. Miklowitz, D. J., Otto, M. W., Frank, E., Reilly-Harrington, N. A., Wisniewski, S. R., Kogan, J. N., & Araga, M. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. *Archives of general psychiatry*, 2007; *64*(4): 419-426.
32. Miklowitz, D. J., Otto, M. W., Frank, E., Reilly-Harrington, N. A., Kogan, J. N., Sachs, G. S., & Patel, J. Intensive psychosocial intervention enhances functioning in patients

with bipolar depression: results from a 9-month randomized controlled trial. *American Journal of Psychiatry*, 2007; *164*(9): 1340-1347.

33. Geddes, J. R., & Miklowitz, D. J. Treatment of bipolar disorder. *The Lancet*, 2013; *381*(9878): 1672-1682.
34. Ford, B. Q., Mauss, I. B., & Gruber, J. Valuing happiness is associated with bipolar disorder. *Emotion*, 2015; *15*(2): 211.
35. Leahy, R. L. Bipolar disorder: Causes, contexts, and treatments. *Journal of clinical psychology*, 2007; *63*(5): 417-424.
36. Perlis, R. H., Miyahara, S., Marangell, L. B., Wisniewski, S. R., Ostacher, M., Delbello, M. P., & Step-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). *Biological psychiatry*, 2004; *55*(9): 875-881.
37. Fountoulakis, K. N., & Akiskal, H. S. Focus on bipolar illness. *CNS Spectr*, 2008; *13*(9): 762.
38. Healy, D., & Le Noury, J. Pediatric bipolar disorder: An object of study in the creation of an illness. *International Journal of Risk & Safety in Medicine*, 2007; *19*(4): 209-221.
39. Berns, G. S., & Nemeroff, C. B. (2003, NOVEMBER). The neurobiology of bipolar disorder. In *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* Wiley Subscription Services, Inc., A Wiley Company., 2003; 123(1): 76-84.